145 related articles for article (PubMed ID: 31838284)
1. Glycan analysis of erythropoiesis-stimulating agents.
Cowper B; Lavén M; Hakkarainen B; Mulugeta E
J Pharm Biomed Anal; 2020 Feb; 180():113031. PubMed ID: 31838284
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive glycan analysis of twelve recombinant human erythropoietin preparations from manufacturers in China and Japan.
Cowper B; Li X; Yu L; Zhou Y; Fan WH; Rao CM
J Pharm Biomed Anal; 2018 May; 153():214-220. PubMed ID: 29502007
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of erythropoietin biosimilars Epotin™, Hemax® and Jimaixin™ by electrophoretic methods used for doping control analysis and specific N-glycan analysis revealed structural differences from original epoetin alfa drug Eprex®.
Capdeville P; Martin L; Cholet S; Damont A; Audran M; Ericsson M; Fenaille F; Marchand A
J Pharm Biomed Anal; 2021 Feb; 194():113750. PubMed ID: 33234415
[TBL] [Abstract][Full Text] [Related]
4. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Three Epoetin Alpha Products by LC and LC-MS Indicates Differences in Glycosylation Critical Quality Attributes, Including Sialic Acid Content.
Thomson RI; Gardner RA; Strohfeldt K; Fernandes DL; Stafford GP; Spencer DIR; Osborn HMI
Anal Chem; 2017 Jun; 89(12):6455-6462. PubMed ID: 28509534
[TBL] [Abstract][Full Text] [Related]
6. Mass spectrometric characterisation of darbepoetin alfa biosimilars with C-terminal arginine residues.
Okano M; Sato M; Kageyama S
Drug Test Anal; 2016 Nov; 8(11-12):1138-1146. PubMed ID: 27706921
[TBL] [Abstract][Full Text] [Related]
7. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).
Macdougall IC; Casadevall N; Locatelli F; Combe C; London GM; Di Paolo S; Kribben A; Fliser D; Messner H; McNeil J; Stevens P; Santoro A; De Francisco AL; Percheson P; Potamianou A; Foucher A; Fife D; Mérit V; Vercammen E;
Nephrol Dial Transplant; 2015 Mar; 30(3):451-60. PubMed ID: 25239637
[TBL] [Abstract][Full Text] [Related]
8. Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS.
Harazono A; Hashii N; Kuribayashi R; Nakazawa S; Kawasaki N
J Pharm Biomed Anal; 2013 Sep; 83():65-74. PubMed ID: 23708432
[TBL] [Abstract][Full Text] [Related]
9. Clinical safety of biosimilar recombinant human erythropoietins.
Abraham I; MacDonald K
Expert Opin Drug Saf; 2012 Sep; 11(5):819-40. PubMed ID: 22880621
[TBL] [Abstract][Full Text] [Related]
10. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
[TBL] [Abstract][Full Text] [Related]
11. UPLC-MS assessment on the structural similarity of recombinant human erythropoietin (rhEPO) analogues from manufacturers in China for attribute monitoring.
Alley W; Tao L; Shion H; Yu YQ; Rao C; Chen W
Talanta; 2020 Dec; 220():121335. PubMed ID: 32928385
[TBL] [Abstract][Full Text] [Related]
12. High Performance Anion Exchange and Hydrophilic Interaction Liquid Chromatography Approaches for Comprehensive Mass Spectrometry-Based Characterization of the N-Glycome of a Recombinant Human Erythropoietin.
Szabo Z; Thayer JR; Reusch D; Agroskin Y; Viner R; Rohrer J; Patil SP; Krawitzky M; Huhmer A; Avdalovic N; Khan SH; Liu Y; Pohl C
J Proteome Res; 2018 Apr; 17(4):1559-1574. PubMed ID: 29451981
[TBL] [Abstract][Full Text] [Related]
13. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer.
Aapro M; Cornes P; Sun D; Abraham I
Ther Adv Med Oncol; 2012 May; 4(3):95-105. PubMed ID: 22590483
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.
Park S; Greenberg P; Yucel A; Farmer C; O'Neill F; De Oliveira Brandao C; Fenaux P
Br J Haematol; 2019 Jan; 184(2):134-160. PubMed ID: 30549002
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.
Lissy M; Ode M; Roth K
Drugs R D; 2011; 11(1):61-75. PubMed ID: 21410296
[TBL] [Abstract][Full Text] [Related]
16. Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.
Halim LA; Brinks V; Jiskoot W; Romeijn S; Haselberg R; Burns C; Wadhwa M; Schellekens H
J Pharm Sci; 2016 Feb; 105(2):542-550. PubMed ID: 26869417
[TBL] [Abstract][Full Text] [Related]
17. Erythropoiesis stimulating agents and techniques: a challenge for doping analysts.
Jelkmann W
Curr Med Chem; 2009; 16(10):1236-47. PubMed ID: 19355882
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP
Jeong YR; Jeong RU; Son JH; Kwon JC; Jung S; Song MA; Hwang JA; Lee GM
BioDrugs; 2018 Apr; 32(2):153-168. PubMed ID: 29556960
[TBL] [Abstract][Full Text] [Related]
19. An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.
Gianoncelli A; Bonini SA; Bertuzzi M; Guarienti M; Vezzoli S; Kumar R; Delbarba A; Mastinu A; Sigala S; Spano P; Pani L; Pecorelli S; Memo M
BioDrugs; 2015 Aug; 29(4):285-300. PubMed ID: 26334631
[TBL] [Abstract][Full Text] [Related]
20. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
Fuller DS; Robinson BM; Locatelli F; Pisoni RL
Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
